Equity Details
Price & Market Data
Price: $1.34
Daily Change: -$0.0102 / 0.76%
Daily Range: $1.33 - $1.38
Market Cap: $453,619,296
Daily Volume: 3,936,042
Performance Metrics
1 Week: -5.55%
1 Month: -24.44%
3 Months: -14.99%
6 Months: 22.53%
1 Year: 66.05%
YTD: 0.01%
About Ocugen, Inc. (OCGN)
Up-to-the-minute market analysis for Ocugen, Inc. (OCGN). Current price: 1.34, daily change: -$0.0102 / 0.76%. Market cap: 453,619,296. Explore all available performance indicators.
Company Details
Employees: 116
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
